Plasma Concentrations of Carminomycin and Carminomycinol in Man, Measured by High Pressure Liquid Chromatography
Overview
Affiliations
In 9 patients with advanced malignant disease who received carminomycin (CMM) in an i.v. bolus injection (dose 18 mg/m2), curves of plasma concentrations of CMM and carminomycinol (CMMOH), a metabolite, versus time were constructed. For determination of plasma concentrations, high pressure liquid chromatography was used. For CMM and CMMOH the median areas under the curves (AUC's) were 31 (range 4-57) X 10(-8) mol/Ql/hr (measured over 24 hr) and 100 (range 309-158) X 10(-8) mol/l/hr (measured over 48 hr) respectively. From the data an accumulation of CMMOH in patients receiving treatments separated by brief intervals ban be predicted (half-life time of plasma disappearance for CMMOH was 2 days). Clinical toxicity was lowest in those 3 patients showing the lowest AUC for both CMM and CMMOH.
Pharmacokinetics of 4'-epi-doxorubicin in man.
Weenen H, Lankelma J, Penders P, McVie J, Ten Bokkel Huinink W, de Planque M Invest New Drugs. 1983; 1(1):59-64.
PMID: 6590528 DOI: 10.1007/BF00180192.
Phase II study of carminomycin in a human tumor cloning assay.
Rozencweig M, Sanders C, Rombaut W, Crespeigne N, Decoster G, Kenis Y Invest New Drugs. 1984; 2(3):267-70.
PMID: 6511232 DOI: 10.1007/BF00175375.
Human pharmacokinetics of esorubicin (4'-deoxydoxorubicin).
Dodion P, Davis T, Rozencweig M, Crespeigne N, Kenis Y, Bachur N Invest New Drugs. 1985; 3(4):361-8.
PMID: 4086243 DOI: 10.1007/BF00170759.
Anticancer drug pharmacodynamics.
Powis G Cancer Chemother Pharmacol. 1985; 14(3):177-83.
PMID: 3888428 DOI: 10.1007/BF00258112.
Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.
Bouma J, Beijnen J, Bult A, Underberg W Pharm Weekbl Sci. 1986; 8(2):109-33.
PMID: 3520474 DOI: 10.1007/BF02086146.